Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 19.92 0.10% 0.02
ACAD closed up 0.1 percent on Monday, April 23, 2018, on 64 percent of normal volume.

Earnings due: May 8

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ACAD trend table...

Date Alert Name Type % Chg
Apr 23 Doji - Bearish? Reversal 0.00%
Apr 23 Multiple of Ten Bearish Other 0.00%
Apr 23 Wide Bands Range Expansion 0.00%
Apr 20 Wide Bands Range Expansion 0.10%
Apr 19 Wide Bands Range Expansion 1.32%
Apr 18 1,2,3 Retracement Bearish Bearish Swing Setup -0.30%
Apr 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.30%
Apr 18 Narrow Range Bar Range Contraction -0.30%
Apr 18 Multiple of Ten Bearish Other -0.30%
Apr 18 Wide Bands Range Expansion -0.30%

Older signals for ACAD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 41.2
52 Week Low 15.74
Average Volume 2,721,516
200-Day Moving Average 29.9217
50-Day Moving Average 24.4049
20-Day Moving Average 20.4865
10-Day Moving Average 19.335
Average True Range 1.2514
ADX 34.78
+DI 18.43
-DI 30.06
Chandelier Exit (Long, 3 ATRs ) 21.0358
Chandelier Exit (Short, 3 ATRs ) 19.4942
Upper Bollinger Band 24.1304
Lower Bollinger Band 16.8426
Percent B (%b) 0.42
BandWidth 35.57367
MACD Line -1.3599
MACD Signal Line -1.6176
MACD Histogram 0.2577
Fundamentals Value
Market Cap 2.44 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -7.87
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.17
Resistance 3 (R3) 21.20 20.82 20.96
Resistance 2 (R2) 20.82 20.50 20.80 20.89
Resistance 1 (R1) 20.37 20.31 20.18 20.34 20.82
Pivot Point 19.99 19.99 19.90 19.97 19.99
Support 1 (S1) 19.54 19.67 19.35 19.51 19.02
Support 2 (S2) 19.16 19.48 19.14 18.95
Support 3 (S3) 18.71 19.16 18.88
Support 4 (S4) 18.68